Protara's Experimental Bladder Cancer Drug Shows Encouraging Results

Protara Therapeutics, Inc. (NASDAQ:TARA) shares are down during Tuesday’s premarket session following the release of updated interim results from the ADVANCED-2 trial of TARA-002, a treatment for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC).

Bladder Cancer Data Shows Response Rate Of 66%

The interim analysis from 35 evaluable participants revealed a 68.2% complete response rate at six months for the BCG-Unresponsive cohort, with no Grade 3 or greater treatment-related adverse events reported.

The complete response (CR) rate at any time was 65.7%.

Among responders, the Kaplan-Meier (KM) estimated probability of maintaining a CR for six months was 71.1%.

100% maintained their complete response from nine to 12 months, and 61.5% of re-induced patients converted to a CR at six months.

In the BCG-naïve cohort, the interim analysis of 27 patients showed a complete response rate of 72.4% at any time, 66.7% at six months, and 57.9% (11 of 19) at 12 months.

Among responders, the KM estimated probability of maintaining a CR for six months was 73.1%, and 100% (11 of 11) maintained their CR from nine to 12 months.

66.7% (4 of 6) of re-induced patients converted to a CR at six months.

Protara expects to complete enrollment of this cohort in the second half of 2026, indicating a promising outlook for TARA-002’s development.

The results highlight TARA-002’s potential as a significant treatment option, particularly given the favorable safety and tolerability profile observed in the trial.

Technical Analysis

Currently, TARA is trading 12.65% below its 20-day simple moving average (SMA), indicating a bearish short-term trend. Over the past 12 months, shares have fluctuated between a high of $7.82 and a low of $2.77, and are currently positioned closer to their 52-week highs than lows.

The RSI is at 50.00, reflecting neutral territory, while MACD is not available for analysis. The absence of a clear MACD signal suggests a lack of momentum in either direction at this time.

The combination of neutral RSI and no MACD data indicates mixed momentum for TARA, suggesting that traders should exercise caution.

• Key Resistance: $7.50
• Key Support: $6.00

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $27.69. Recent analyst moves include:

• HC Wainwright & Co.: Buy (Maintains Target to $23.00) (Feb. 10)
• Piper Sandler: Initiated with Overweight (Target $24.00) (Jan. 7)
• HC Wainwright & Co.: Buy (Maintains Target to $23.00) (Dec. 3, 2025)

TARA Price Action: Protara Therapeutics shares were down 7.94% at $6.84 during premarket trading on Tuesday, according to Benzinga Pro data.

Photo by Aunt Spray via Shutterstock